Generation Bio Co. (GBIO) is a publicly traded company in the Unknown sector. Across all available filings, 29 corporate insiders have executed 426 transactions totaling $113.6M, demonstrating a bullish sentiment with $27.2M in net insider flow. The most recent transaction on Jan 15, 2026 involved a transaction of 395 shares valued at $0.
No significant insider buying has been recorded for GBIO in the recent period.
No significant insider selling has been recorded for GBIO in the recent period.
Based on recent SEC filings, insider sentiment for GBIO is bullish with an Insider Alignment Score of 62/100 and a net flow of $27.2M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Generation Bio Co. (GBIO) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 29 insiders are actively trading GBIO stock, having executed 426 transactions in the past 90 days. The most active insider is Biomedical Innovation Master Investors (cayman) I. L.p. Wellington (Executive), who has made 2 transactions totaling $20.9M.
Get notified when executives and directors at GBIO file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 15, 2026 | Mcdonough Geoff | Executive | Option Exercise | 395 | $N/A | $0 | |
| Jan 15, 2026 | Mcdonough Geoff | Executive | Payment | 137 | $5.64 | $773 | |
| Jan 15, 2026 | Mcdonough Geoff | Executive | Option Exercise | 395 | $N/A | $0 | |
| Jan 15, 2026 | John Conway Kevin | Chief Financial Officer | Option Exercise | 59 | $N/A | $0 | C-Suite |
| Jan 15, 2026 | John Conway Kevin | Chief Financial Officer | Payment | 17 | $5.64 | $96 | C-Suite |
| Jan 15, 2026 | John Conway Kevin | Chief Financial Officer | Option Exercise | 59 | $N/A | $0 | C-Suite |
| Oct 31, 2025 | Mcdonough Geoff | Executive | Payment | 293 | $5.51 | $1.6K | |
| Oct 31, 2025 | Mcdonough Geoff | Executive | Option Exercise | 659 | $N/A | $0 | |
| Oct 15, 2025 | John Conway Kevin | Executive | Option Exercise | 58 | $N/A | $0 | |
| Oct 15, 2025 | John Conway Kevin | Executive | Payment | 18 | $6.71 | $121 | |
| Oct 15, 2025 | Paone Antoinette | Executive | Payment | 47 | $6.71 | $315 | |
| Oct 15, 2025 | Paone Antoinette | Executive | Option Exercise | 159 | $N/A | $0 | |
| Oct 15, 2025 | Howze Yalonda | Executive | Payment | 99 | $6.71 | $664 | |
| Oct 15, 2025 | Howze Yalonda | Executive | Option Exercise | 334 | $N/A | $0 | |
| Oct 15, 2025 | Mcdonough Geoff | Executive | Payment | 155 | $6.71 | $1.0K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 23 | $70.4M | 61.2% |
Sale(S) | 167 | $43.2M | 37.5% |
Payment(F) | 87 | $861.6K | 0.7% |
Exercise(M) | 123 | $560.4K | 0.5% |
Award(A) | 1 | $48.6K | 0.0% |
Gift(G) | 4 | $0 | 0.0% |
Other(J) | 6 | $0 | 0.0% |
Conversion(C) | 15 | $0 | 0.0% |
Insiders at Generation Bio Co. are accumulating shares at an accelerated pace. With 29 insiders making 426 transactions totaling $70.4M in purchases versus $43.2M in sales, the net buying activity of $27.2M signals strong executive confidence. Biomedical Innovation Master Investors (cayman) I. L.p. Wellington (Executive) leads the buying activity with $20.9M in transactions across all time.